MEGHANA TRIVEDI to Antineoplastic Agents, Hormonal
This is a "connection" page, showing publications MEGHANA TRIVEDI has written about Antineoplastic Agents, Hormonal.
Connection Strength
1.851
-
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
Score: 0.628
-
Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Cancer Surviv. 2018 06; 12(3):348-356.
Score: 0.533
-
Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 2011 Oct; 20 Suppl 3:S42-9.
Score: 0.344
-
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.
Score: 0.176
-
The changing role of ER in endocrine resistance. Breast. 2015 Nov; 24 Suppl 2:S60-6.
Score: 0.112
-
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
Score: 0.030
-
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
Score: 0.028